USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
BIOHELIX CORPORATION
Address:
500 Cummings Center
BEVERLY, MA
Phone:
N/A
URL:
N/A
EIN:
201484089
DUNS:
169510950
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $3,289,183.00 12
SBIR Phase II $6,275,891.00 4
STTR Phase I $482,810.00 1

Award List:

Kilo-base Range Isothermal DNA Amplification

Award Year / Program / Phase:
2005 / SBIR / Phase II
Award Amount:
$741,335.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The ability to amplify and subsequent detection a target sequence with a limited length may satisfy the need for diagnosing some of the diseases. Nevertheless, much biomedical research, such as cloning genes and analysis of genetics variation, often demands… More

Helicase-based rapid DNA diagnostic for Biodefense

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$934,198.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Nucleic acid based diagnostic devices allow accurate identification of biological agents by specifically amplifying specific target sequences from environmental samples. Current diagnostic tests rely on PCR, a more costly and time-consuming detection method that… More

True-Isothermal Plasmid Amplication System

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$98,208.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Amplification and detection of specific target sequences from DMA and RNA is a fundamental tool for diagnostics and biomedical research. We have devised a new isothermal DMA amplification method which can be used to amplify circular DMA molecules, by mimicking… More

Development of a one-step isothermal DNA amplification system for diagnostics

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$126,202.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Molecular diagnostic tests that rely on the amplification of specific sequences to identify genes of interest frequently use the polymerase chain reaction (PCR). To perform PCR, sensitive and, often, expensive instrumentation is required for thermocycling, which… More

Pyrophosphorolysis-activatable helicase dependent amplification assay for lung ca

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$141,267.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Aside for a vast minority of asymptomatic patients diagnosed incidentally, virtually all lung cancer patients are symptomatic at presentation. As a result only 30-35% of patients have sufficiently localized tumo rs to allow for surgical resection of the… More

Development of a novel whole genome amplification method that mimics nature

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$110,579.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): BioHelix is the exclusive licensee for the commercialization of a novel, primase- based Whole Genome Amplification (pWGA) technology invented by Drs. Stanley Tabor and Charles Richardson at Harvard Medical School. This pWGA system utilizes multiple replication… More

Lateral flow assay for detecting colonization by Streptococcus agalactiae

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$201,042.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Streptococcus agalactiae, a.k.a. group B streptococcus (GBS), is one of the leading causes of morbidity, and mortality among newborns. We propose to develop a molecular assay for GBS using our proprietary helicase depe ndent amplification (HDA), and a lateral… More

Development of a novel whole genome amplification method that mimics nature

Award Year / Program / Phase:
2008 / SBIR / Phase II
Award Amount:
$805,716.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): BioHelix is the exclusive licensee for a novel, primase-based Whole Genome Amplification (pWGA) technology invented by Drs. Stanley Tabor and Charles Richardson at Harvard Medical School. This pWGA system utilizes multi ple replication proteins including a… More

Herpes virus typing assay for detecting genital herpes

Award Year / Program / Phase:
2008 / SBIR / Phase II
Award Amount:
$1,893,838.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The objective of our NIAID Biodefense Phase I SBIR program was to develop, and commercialize field deployable nucleic acid analysis devices for use in biodefense applications. We have begun to sell IsoAmp II kits that will allow our clients to develop home brew… More

Lateral flow molecular assay for horse strangles

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$80,000.00
Agency:
USDA
Principal Investigator:
Bertrand Lemieux, S. Director of Technology Development
Abstract:
This proposal seeks to develop a simple, and sensitive molecular diagnostic assay for the detection of Streptococcus equi; the causative agent of strangles. Outbreaks of this disease at racetracks and training establishments caused major disruptions, and economic losses to owners, and trainers in… More

Point of care genotyping assays, and algorithm for warfarin dosing

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$155,774.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): On August 16, 2007, the FDA updated the label for warfarin to include information in the precautions section to remind physicians that people with variations in the CYP2C9 and VKORC1genes may require a lower initial d ose of the drug (see… More

Low cost molecular assay for HIV

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$151,440.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): We propose to develop a rapid, low cost, threshold assay for the detection of HIV infection of HIV vaccination trial participants. Infection by HIV, and viral load are the usual end points for Phase III HIV vaccination trials. Ongoing Phase III HIV vaccine… More

Low cost molecular assay for HIV

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$2,835,002.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): We propose to develop a rapid, low cost, threshold assay for the detection of HIV infection of HIV vaccination trial participants. The assay we propose to develop will use our proprietary helicase dependent amplificatio n (HDA) platform as well as a low cost… More

Genotyping assays for the most common mutations associated with abacavir hypersen

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$143,606.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): We propose to develop a near patient assays to score 2 SNPs associated with abacavir-severe cutaneous adverse reactions (SCAR); i.e., HLA B*5701 and the Hsp70-Hom M493T allele (a.k.a. rs2227956CT). Nucleic acid template s will be isolated from cells obtained from… More

Molecular tests for malaria that can be performed with unprocessed samples

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$546,867.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): This SBIR-AT-NIAID Phase I application addresses the problem of malaria diagnostics in resource- limited settings. BioHelix, has developed an isothermal nucleic acid amplification chemistry called helicase dependent amp lification (HDA) that is tolerant of the… More

Integrated molecular diagnostic system for the point-of-care

Award Year / Program / Phase:
2011 / STTR / Phase I
Award Amount:
$482,810.00
Agency:
HHS
Principal Investigator:
Huimin Kong – 978-927-5056
Research Institution:
BOSTON UNIVERSITY
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): This STTR-AT-NIAID seeks to develop an integrated nucleic acid system based on research done by Catherine Klapperich's laboratory at Boston University. The BU lab-on-a-chip includes a micro solid phase extraction (lt SPE) column, flap valves and hydrophobic… More

Low-cost, rapid quantitative Isothermal Assay for HIV RNA using ZNA

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
Huimin Kong – 978-927-5056
Abstract:
DESCRIPTION (provided by applicant): In this Phase I project, we propose to investigate a novel primer chemistry and probe detection system called the Zip nucleic acids (ZNA ). ZNAs are oligonucleotides conjugated to a number of cationic spermine moietiesthat enhance the effective concentration of… More